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Abstract
Background—Hepatitis B virus (HBV) infection, the predominant cause of hepatocellular 
carcinoma (HCC) worldwide, disproportionately affects Asian Americans. Limited data exists on 
the variability and characteristics of infection that determine disease progression risk within US 
Asian ethnic subgroups.
Methods—Retrospective analyses were conducted on a large, community-based HBV screening 
and treatment program in New York City (NYC). From 2005-2008 the program enrolled 7,272 
Asian-born individuals. Determinants of HBV seroprevalence were calculated and risk factors for 
HCC progression were compared across Asian subgroups.
Results—Among newly tested individuals, 13% were HBV positive. Seroprevalence varied 
significantly with age, gender, education, birthplace, and family history of infection. Chinese-born 
individuals, particularly from the Fujian province, had the highest seroprevalence (23.2% and 
33.1%, respectively). Clinical and virologic characteristics placed HBV-infected individuals at 
significant risk for HCC. Significant differences in HCC risk existed among Asian subgroups in 
bivariate analysis, including age, gender, HBV viral load and HBeAg status. Differences in HBV 
genotype and family history of HCC may further HCC risk among subgroups.
Conclusions—Asian immigrants in NYC have a high prevalence of HBV infection and are at 
significant risk of disease progression and HCC. Although heterogeneity in HBV seroprevalence 
was found by Asian subgroups, HCC risk among infected individuals was primarily explained by 
age and gender differences. Country and province of birth, age, and gender may further explain 
seroprevalence differences.
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Impact—Findings provide estimates of HBV burden in Asian ethnic subgroups and identify high 
risk groups to target for screening and treatment that can prevent HCC.
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Introduction
Hepatocellular carcinoma (HCC) is the most frequent type of primary liver cancer 
worldwide, accounting for about 80% of liver cancers and approximately 500,000 deaths 
annually (1, 2). Hepatitis B (HBV) is the leading underlying cause of HCC, and a strong 
correlation is demonstrated between the prevalence of hepatitis B surface antigen (HBsAg) 
and HCC (3, 4). Approximately 5% of the world population (300-400 million) is chronically 
infected with HBV; 75% of whom are Asian (5, 6). More than two-thirds of new, worldwide 
liver cancer cases occur in Asian countries (7), and in China alone, an estimated 383,203 
deaths in 2012 was attributed to liver cancer (8).
In the United States (US), the number of newly diagnosed cases of primary liver cancer each 
year is less than one-tenth that of China; in 2013, there were an estimated 30,640 new cases 
of liver cancer and 21,670 deaths in the US (9). The burden of disease is greatest among 
Asian Americans, for whom the incidence of liver cancer is 2 times greater than in non-
Hispanic whites (10, 11). Liver cancer incidence and mortality rates are especially high 
among Asian American men, most notably Vietnamese men (12). In a recent study of age-
adjusted cancer mortality rates among Asian Americans in New York City (NYC) (5), 
Korean males had the highest liver cancer mortality rate compared to all racial/ethnic 
groups, and rates among Chinese men were 2.5 times higher than rates for non-Hispanic 
white men (5). Liver cancer was the second and third cause of cancer deaths in NYC 
Chinese and Korean men, respectively. The difference in rates are related to the prevalence 
of HBV, but could include other potential factors that contribute to the development of HCC 
(6), such as aflatoxin exposure (13, 14), alcohol consumption (15), family history of HCC 
(16, 17), and HBV genotype (18, 19).
While less than 0.5% of the US population tests positive for HBsAg, the prevalence of 
chronic HBV infection among Asian Americans is estimated to be between 9 and 15%, and 
may be as high as 25% in select subgroups of recent immigrants (20-26). Asian Americans, 
the fastest growing racial/ethnic group in the US, are largely foreign-born (27) and account 
for 60% of persons in the US with chronic HBV (28). However, Asian Americans represent 
over 30 ethnic subgroups characterized by tremendous diversity, including differences in 
socioeconomic status (SES), access to resources, migration patterns, and immigration 
histories. While recent studies have increasingly focused on the epidemiology of HBV 
infection among Asian Americans in the aggregate (29, 30), research on infection 
disaggregated by subgroup has lagged, and few studies exist on the specific virologic 
characteristics and progression of disease in Asian subgroups in the US, particularly among 
those identified by community screening programs (30-32).
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The majority of published literature on the progression of HBV infection comes from studies 
conducted in HBV-endemic countries, clinical patient trials, or hepatology patient clinical 
data. These studies have shown that the major determinant of disease progression and HCC 
in chronically infected persons is the level of HBV viral load (VL) in the blood. High levels 
of plasma HBV VL have been shown to be strong predictors for the risk of HCC (33). 
Hepatitis B e antigen (HBeAg), a HBV protein found in the blood when HBV is replicating 
at high rates, has also been associated with a 60-100-fold increase in the risk of HCC (34). 
More recently, studies have used a combination of these risk factors, including HBV VL, 
age, gender, HBeAg status, and HBV genotype to more accurately model HCC risk (18). 
Moreover, antiviral therapy is indicated for a subgroup of HBV patients and has been shown 
to reduce progression of fibrosis, reduce or even reverse cirrhosis (35, 36), and mitigate risk 
of HCC (37). Various guidelines have been developed by American Association for the 
Study of Liver Diseases (AASLD) (38), the European Association for the Study of the Liver 
(EASL) (39, 40), and the Asian Pacific Association for the Study of the Liver (APASL) (41) 
for initiating antiviral therapy in individuals at greatest risk of progression and sequalae. 
Limited information, however, is available on the actual burden of disease and the risks of 
progression and complications among the larger population of HBV-infected Asians, or by 
Asian subgroups, in the US. Accurate statistics on HBV infected individuals are important in 
assessing and targeting public health needs and estimating future health care costs related to 
HBV infection.
In this study, we attempt to address these gaps in knowledge by analyzing retrospective data 
from a community-based screening, care, and treatment program, the Asian American 
Hepatitis B Program (AAHBP), implemented from 2004 to 2008 in NYC, home to the 
biggest Asian American population (42). AAHBP, the largest screening program of Asian 
Americans and the original prototype of linkage-to-care approaches in the US (43), was 
unique in that it collected detailed demographic data on participants and provided no-cost 
evaluation and treatment to HBsAg positive individuals. In this study, we analyze the 
prevalence of chronic HBV infection by Asian ethnic subgroup, the predictors of HBsAg 
positivity, and the clinical and virologic characteristics of HBV-infected individuals in order 
to develop a more complete and nuanced understanding of the burden of disease and risk of 
progression and HCC outcome in this population.
Materials and Methods
Study Population
AAHBP was a city-wide collaboration of community-based organizations, academic 
institutions, community health centers, and the NYC Department of Health and Mental 
Hygiene (DOHMH) that provided no-cost HBV screening, vaccination, and treatment (43, 
44). The program adopted a comprehensive strategy to increase HBV awareness, provide 
community-based outreach and education, and conduct free HBV screening and vaccination, 
which included follow-up medical care and treatment to HBV-positive individuals. The 
study was approved by the Institutional Review Boards of New York University School of 
Medicine and the DOHMH.
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Between January 2005 and June 2008, individuals were offered HBV serologic testing at 
education and screening events or by drop-in at 12 participating health care centers and 
community-based organizations serving Asian Americans throughout NYC. Comprehensive 
post-screening clinical evaluation, care, and treatment were provided to HBV-infected 
individuals. Demographic and epidemiologic information was collected at the time of 
screening and clinical information was collected for HBsAg-positive individuals returning 
for follow-up visits. Positive individuals were evaluated at the AAHBP Hepatitis Clinics at 
Bellevue Hospital Center, Gouverneur Healthcare Services or Charles B Wang Community 
Health Center. Additionally, HBsAg positive individuals referred to AAHBP clinics by the 
DOHMH were included in the analysis of the clinical results for HBsAg positive 
individuals.
A total of 7,272 individuals aged 18 and over, who were born in an Asian country and had 
confirmed HBsAg results participated in AAHBP. Among these individuals, 4,301 (59.1%) 
had not previously received or did not know if they had received a HBV screening.
Laboratory Tests
Blood samples were tested for HBsAg and hepatitis B surface antibody (HBsAb) using 
ELISA tests (Immulite 2000, DPC, Los Angeles, CA) within 72 hours of collection. 
Individuals testing positive for HBsAg were further evaluated by physical exam and 
additional laboratory investigations were performed, including hepatitis B e-antigen 
(HBeAg), a marker of active viral disease, alanine aminotransferase (ALT), a liver enzyme 
marker, and HBV VL, a measure of how much virus is present. The upper limit of normal 
ALT levels was defined as 30 U/L for men and 20 U/L for women per the AASLD Practice 
Guidelines (45).
Statistical Analysis
Prevalence estimates and 95% confidence intervals (CIs) were calculated for newly screened 
individuals as previously described (46). Adjusted logistic regression was performed using 
demographic and risk factors that were statistically significant in bivariate analysis at 
(α<0.05); odds ratios (ORs) and 95% CIs are presented. Separate analyses were performed 
on all newly screened Chinese and Korean participants. Clinical characteristics for all 
HBsAg positive individuals, regardless of prior screening, were assessed for all individuals 
receiving detailed clinical testing. Clinical characteristics were stratified by country of birth 
and province of birth where applicable. HBsAg+ subjects’ initial intake ALT and HBV VL 
were used in an analysis looking at participants who might meet previously described 
guidelines for antiviral therapy (37, 39, 40, 45). All guidelines recommend treating patients 
with ALT > 2 times the upper limit of normal (2xULN) and HBV VL ≥100,000 copies/ml. 
Additional analyses were performed as needed to explain clinical characteristics of infected 
individuals. All analyses were conducted using SPSS version 20.0 (Armonk, NY: IBM 
Corp).
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Among 4,301 newly screened, Asian-born individuals, approximately 49% were born in 
China, 36% in Korea, 9% in Malaysia, 1% in the Philippines, 1% in Taiwan, 2% in South 
Asia (India, Pakistan, or Bangladesh), 1% in Vietnam, and 1% in another Asian country 
(Table 1). A total of 574 individuals (13.3%) tested positive for HBsAg.
Infection rates were highest among Chinese (23.2%) and Taiwanese (13.3%), and lowest 
among Koreans (3.8%) and Malaysians (3.1%). Males were significantly more likely to be 
HBsAg positive compared to females (18.8% vs. 7.9%). Male gender, younger age, 
birthplace in China, Malaysia, and Taiwan, lower education, fewer years lived in the US, 
and a family history of HBV were significantly related to HBsAg positivity in bivariate 
analysis. Once placed into adjusted logistic regression, years lived in the US was no longer 
significant. Newly screened, Asian-born individuals testing positive for HBsAg were 
significantly more likely to be male, younger in age, Chinese-born, to have attained lower 
levels of education, and to have a family history of HBV.
Among the subset of newly screened Chinese-born individuals (Table 2), approximately 
53.5% were born in the Fujian province; the prevalence of HBsAg positivity was 
significantly higher among individuals born in the Fujian province compared to those born 
in other Chinese provinces (33.1% vs. 11.7%). Further differences by province are shown in 
Figure 1. Male gender, younger age, birthplace in the Fujian province, fewer years lived in 
the US, lower education, and a family history of HBV were significantly related to HBsAg 
positivity in bivariate analysis. Once placed into adjusted logistic regression, years lived in 
the US was no longer significant. Newly screened, Chinese-born individuals testing positive 
for HBsAg were significantly more likely to be male, in a younger age group, born in the 
Fujian province, to have attained lower levels of education, and to have a family history of 
HBV.
Among the subset of newly screened individuals born in Korea (Table 3), males were 
significantly more likely than females to be HBsAg positive (4.9% vs. 2.9%), and 
individuals with a family history of HBV were more likely to be HBsAg positive compared 
to individuals without a family history of HBV (11.5% vs. 3.2%). Once placed into adjusted 
logistic regression, male gender and family history of HBV remained significant for newly 
screened, Korean-born individuals testing positive for HBsAg.
Characteristics of HBV-Infected Subjects
Clinical characteristics and HCC development among HBV-infected—All 
individuals were asymptomatic when initially evaluated, with no overt evidence of liver 
disease. Among the 1,620 individuals found to be HBsAg positive regardless of previous 
screening, 1,227 (75.7%) had further tests performed at AAHBP clinics (Table 4). Overall, 
32% of participants were HBeAg positive. More than 70% of participants had a detectable 
HBV VL (≥300 copies/mL), signifying active viral replication, and 24% had HBV VL ≥ 
1,000,000 copies/mL associated with a high risk of HCC. Approximately 18% of 
participants had ALT > 2xULN.
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During the course of follow-up, 7 individuals developed HCC. Six were from China and one 
was from Korea. Six of the individuals were male. The median age was 50, and 5 out of the 
6 Chinese individuals were born in the Fujian province. Twenty-two individuals were 
diagnosed with cirrhosis on the basis of liver biopsy or MRI.
Estimation of HCC Risk (Surrogate Markers of HCC Risk)
Using known major predictors of HCC including HBeAg, HBV VL, genotype, 
family history of HCC—Among infected individuals, Chinese were most likely to be 
younger and male, while Koreans were older and had lived longer in the US (see Table 4). 
Among Chinese, individuals from the Fujian province were more likely to be younger and 
male compared to individuals from outside of the Fujian province. Chinese were 
significantly more likely to be HBeAg positive than Koreans and Malaysians, and Chinese 
from the Fujian province were significantly more likely to be HBeAg positive than 
individuals born in another Chinese province. The distribution of HBV VL differed 
significantly by Asian subgroup, and median HBV VL was higher among Chinese and 
Malaysians compared to Koreans. Initial comparisons of HBV VL and HBeAg stratified by 
age bracket suggested differences between Chinese and Koreans; however, logistic 
regression analyses (not shown) indicated that younger age and male gender were the major 
determinants of differences in higher HBV VL among Koreans and Chinese. Younger age 
was the major determinant of differences in positive HBeAg and higher ALT among 
Koreans and Chinese as well as higher HBV VL and positive HBeAg among Chinese.
Genotype data was available on patients at one clinical site. Among 105 Chinese, 42% were 
genotype B and 57% were genotype C; among 16 Koreans, 100% were genotype C; and 
among 4 Malaysians, 50% were genotype B and 50% were genotype C. Family history of 
HCC was obtained on around 50% of participants; descriptive information is provided on 
862 Chinese, 124 Koreans, and 36 Malaysians. Approximately 12.3% of Chinese, 25% of 
Koreans, and 22.2% of Malaysians reported a family history of HCC.
Using specific guidelines for starting antiviral treatment as an approximate 
indicator of progression and HCC risk—Using calculations based on established 
guidelines (37, 39, 40, 45), approximately 11% of HBV-infected persons meet criteria for 
treatment, with higher rates for Fujianese Chinese (11.7%) and Korean (12.0%) individuals 
(Table 5). Many individuals with lower HBV VL and ALT might also be treated, especially 
when considering additional risk factors such as age, gender, family history of HCC, viral 
mutations, and genotype. Individuals with HBV VL between 10,000 and 100,000 copies/mL 
and ALT 2xULN, an additional 7.9%, might also be treated (per APASL guidelines), 
although in this case, proportionately more Koreans (8.8%) and Malaysians (20.6%) than 
Chinese (7.0%) would be treated.
Discussion
We found that the overall seroprevalence of chronic HBV infection among Asian 
immigrants participating in a community-based screening program in NYC was very high; 
13.4% of newly-tested individuals had chronic HBV infection. Male gender, younger age, 
lower education, and family history of HBV infection were associated with higher HBV 
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prevalence. The most important determinant of prevalence was country of birth; this was 
especially true for Chinese (23.1%) compared to most other groups. Among Chinese, there 
was further diversity in the seroprevalence rates related to geographic location; the highest 
seroprevalence was seen among individuals from Fujian province.
HBV infection in Asian immigrants in NYC closely mirrors the epidemiology of HBV in 
Asia (47). The prevalence in Chinese immigrants grouped by province/region of birth is 
similar to that found in China with the exception of the Fujian province (7, 8, 10). The 
prevalence of chronic HBV in Fujianese immigrants in our study was more than twice the 
rate (17.1%) reported for the Fujian province in the China National Survey, the province 
with the highest HBV infection prevalence in China (7, 11, 25, 26). Higher infection rates 
among the Fujianese in our sample may be due to specific migration-related factors that 
overlap with HBV risk factors. For example, it has been estimated that 80% of Fujianese 
immigrants to the US reside in NYC – numbering between 300,000-500,000 – with the 
majority migrating from the rural eastern costal region around the capital of Fuzhou (48); 
these are regions found to have higher HBV infection rates (49). Putian County in Fujian 
was found to have the highest infection rate (27.5%) (11), similar to that found among 
Fujianese immigrants in our study. A recent study conducted in Fujian province identified 
individuals who are 15-24 years of age, male, with lower educational attainment, and 
demographic characteristics that correspond with those of Fujianese participants in our 
study, were more likely to immigrant internationally from Fujian (50).
The large variation in HBsAg seroprevalence reported in studies conducted across the US 
(51) may be a reflection of differences in migration patterns of Asian-born immigrants in 
that region. For example, the prevalence rates in Chinese immigrants in the northeast where 
Fujianese immigrants have predominantly settled are generally higher than prevalence rates 
from western regions in the US that are predominantly settled by Chinese immigrants from 
Hong Kong, where HBV seroprevalence is much lower (48). Consequently, the burden of 
HBV and its complications is expected to be higher in areas populated by Asians emigrating 
from countries and specific geographic areas with higher HBV seroprevalence.
The true burden of disease, however, requires more than just knowledge of seroprevalence 
rates. Individual risk of liver disease and HCC are important co-factors. The clinical and 
virologic data obtained on HBV-infected subjects in this study indicate that a large 
proportion of Asian Americans with chronic HBV infection have a high risk of developing 
HCC. Furthermore, this risk is not homogeneous: the clinical data presented indicate 
significant heterogeneity in the virologic and host factors that are highly associated with risk 
of HCC. The interpretation of these differences is complex. In general, Fujianese immigrants 
have higher HBV VLs and a greater proportion of HBeAg positivity than Koreans or 
Chinese from other provinces. We found that 22 individuals were diagnosed with cirrhosis 
on the basis of liver biopsy or MRI. This likely underestimates the true prevalence, as liver 
biopsies were only performed for clinical indications such as elevated AFP, persistently 
elevated ALT, or abnormal ultrasound or MRI.
In our analysis, however, these findings mostly reflect differences in the age and gender 
distributions among these groups, with Fujianese immigrants being significantly younger 
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and male, correlating with HBeAg positivity and higher HBV VL. Therefore, in ascribing 
risk and comparing subjects in one study to another, it is important to take age and gender 
into consideration. We observed two important risk factors that were significantly different 
by subgroup: genotype and family history of HCC (16). Koreans had a much higher 
proportion of genotype C, which is associated with a higher risk of HCC (52, 53). This is 
consistent with data from Korea where nearly 100% of HBV-infected patients are infected 
with genotype C2 (54). Similarly, the distribution of genotypes for Chinese individuals is 
consistent with data from China (55). Additionally, nearly twice as many Koreans reported 
family members with HCC. Genotype and family history may explain why NYC Koreans 
have a higher risk of HCC (5). Factors such as alcohol intake, genetic predisposition and 
aflatoxin may also affect risks differences between groups. Fujianese immigrants appear 
more likely to develop HCC at an early age (56) for reasons that are still unclear, but are 
likely related to some of those factors. Risk stratification using a comprehensive scoring 
system that accounts for age, gender, HBV VL, HBeAg status, and family history of HCC 
and genotype (18) may potentially provide a better way to calculate disease burden in 
specific subgroups and more effectively target individuals at a greater risk for HCC and for 
whom treatments may bring the greatest benefit. Treatment is at the present time the only 
way to significantly reduce the risk of HCC and other complications of HBV. Screening for 
HCC among those at highest risk using ultrasound and serology are also important in 
allowing for treatment initiation at an early stage of malignancy resulting in better outcomes.
The present analysis is the first large in-depth study of HBV infection in Asian Americans in 
NYC. Potential limitations should be considered in the interpretation of the study findings. 
The screening program may have attracted participants with known chronic HBV infection 
seeking treatment. However, our estimate of HBV seroprevalence within the community is 
conservative and is based on the group of newly screened participants, defined as those who 
reported no prior HBV screening (46). The results were comparable to those reported in 
different Asian countries and specific Chinese regions. In addition, findings may be specific 
to NYC’s immigrant communities and may not be generalizable to other Asian populations 
in the US. As presented earlier, 80% of all Fujianese immigrants to the US reside in NYC; 
thus, contextual factors including migration history and patterns need to be considered. 
Estimates of the HBV prevalence among Asian Americans should take into consideration 
both the country and geographic area of birth among immigrant populations.
We believe that our findings are an accurate reflection of the current disproportionate burden 
of chronic HBV infection among Asian immigrants living in NYC. For example, the 
DOHMH conducted an investigation of a randomly selected representative sample of newly 
reported HBV cases from 2008-2009. Findings indicate that 61% of HBV patients were 
male, 67% Asian (56% indicated their birth country as China) and the median age was 38 
years (57). However, HBV prevalence is not static, and changes expected in the 
epidemiology of HBV in Asia will eventually have a profound effect on the prevalence of 
HBV in new Asian immigrants. We expect to see a decline in HBV infection rates among 
younger Asian immigrants from countries such as Korea and China where national newborn 
hepatitis B vaccination programs have only recently been implemented (58-60).
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Although mass HBV vaccination programs will eventually lead to a decrease in the number 
of imported cases of chronic HBV, the absolute number of cases will likely continue to rise 
for some time due to current immigration patterns. Many Asian adults born prior to the 
institution of universal vaccination will continue to migrate to the US, and at the same time a 
large reservoir of persons chronically infected remains undetected in the US. HBV infection 
and its sequelae will continue to be a serious US public health challenge for decades to 
come. For example, despite ongoing public health efforts from 1990 to 2008, liver cancer 
incidence among Asian Americans have increased (61). It will become increasingly 
important to detect asymptomatic cases of HBV and provide early evaluation and treatment 
to prevent chronic liver diseases, hepatic failure and HCC. The results of this study may 
have practical implications for the prevention and management of the disease in other Asian 
communities in the US (57). Despite high HBV prevalence, screening rates for HBV among 
Asian Americans continue to be insufficient. Nearly two-thirds of foreign-born HBV-
infected Asian Americans are unaware of their infection status (20, 25) and between 40 and 
65% of Asian Americans have not been screened for HBV (62). Community-based 
screening programs to address this burden of HBV across Asian populations in the US that 
are culturally tailored and targeted within specific high risk groups are needed. Along with 
screening and early detection of HBV infection, however, further evaluation and active 
monitoring is absolutely essential to reducing the risk of death from HCC to ensure needed 
antiviral treatment and active monitoring of liver cancer is provided (63-66).
In summary, Asian immigrants in NYC have a high rate of chronic HBV infection and a 
substantial ongoing risk for liver cancer. HBV seroprevalence varies considerably by ethnic 
subgroup and geographic place of birth, whereas the risk of disease progression and HCC 
among infected individuals appears relatively uniform except where there are large 
differences in HBV genotype. While Fujianese immigrants have the highest HBV 
seroprevalence, the risk of liver cancer is higher in HBV-infected individuals born in Korea 
because of the very high rate of genotype C infection. More studies are needed to accurately 
ascertain and predict HCC risk in order to better inform public health strategies that target 
high risk subgroups for screening, and HBV disease management. Early antiviral treatment 
and liver cancer monitoring for those at risk are absolutely key to reducing the burden of 
disease in individuals already infected.
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Table 1
Prevalence and predictors of HBsAg+ among all newly screened foreign-born Asians, n=4,301
N (%) Prevalence (95% CI) ORa (95% CI) p-value
Gender
 Male 2139 (49.7) 18.8 (17.1, 20.5) 2.4 (1.9, 2.9) <0.001
 Female 2162 (50.3) 7.9 (6.8, 9.0) 1.0
Age
 18-29 762 (17.7) 24.7 (21.6, 27.8) 5.0 (2.4, 10.5) <0.001
 30-39 874 (20.3) 19.8 (17.2, 22.4) 4.0 (2.0, 8.3) <0.001
 40-49 990 (23.0) 11.6 (9.6, 13.6) 2.8 (1.3, 5.7) 0.006
 50-59 955 (22.2) 7.4 (5.7, 9.1) 1.9 (0.9, 3.9) 0.095
 60-69 505 (11.8) 2.8 (1.4, 4.2) 0.9 (0.4, 2.1) 0.767
 70+ 215 (5.0) 6.0 (2.8, 9.2) 1.0
Country of Birth
 China 2088 (48.5) 23.2 (21.4, 25.0) 3.5 (2.5, 4.9) <0.001
 Korea 1551 (36.1) 3.8 (2.9, 4.8) 1.0
 Malaysia 381 (8.9) 3.1 (1.4, 4.8) 0.5 (0.3, 1.0) 0.044
 Philippines 53 (1.2) 3.8 (-1.4, 9.0) 1.5 (0.3, 6.2) 0.614
 Taiwan 60 (1.4) 13.3 (4.7, 21.9) 4.4 (2.0, 10.0) <0.001
 South Asia 69 (1.6) 7.2 (1.1, 13.3) 1.2 (0.4, 3.6) 0.711
 Vietnam 40 (0.9) 5.0 (-1.8, 11.8) 1.2 (0.3, 5.0) 0.839
 Other Asian country 59 (1.4) 1.7 (-2.4, 5.8) 0.4 (0.1, 2.8) 0.339
Years in US
 Less than 5 714 (16.6) 18.2 (15.4, 21.0) 1.1 (0.8, 1.4) 0.676
 5 to 10 1413 (32.9) 15.2 (13.3, 17.1) 0.9 (0.7, 1.1) 0.202
 More than 10 1841 (42.8) 10.5 (9.1, 11.9) 1.0
 Unknown 333 (7.7) 10.5 (7.2, 13.8) 0.8 (0.5, 1.3) 0.357
Education
 Elementary school 533 (12.8) 16.5 (13.4, 19.7) 2.4 (1.6, 3.5) <0.001
 Junior high school 1047 (25.1) 21.0 (18.5, 23.5) 2.0 (1.4, 2.7) <0.001
 High school/vocational school 1427 (34.2) 13.6 (11.8, 15.4) 1.7 (1.2, 2.3) 0.002
 College 1164 (27.9) 6.5 (5.1, 7.9) 1.0
Family History of HBV
 No 2625 (61.3) 9.9 (8.8, 11.0) 1.0
 Yes 561 (13.1) 26.9 (23.2, 30.6) 2.3 (1.8, 3.0) <0.001
 Not sure 1095 (25.6) 14.5 (12.4, 16.6) 1.3 (1.0, 1.6) 0.037
a
Adjusted for all other variables in the model
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Table 2
Prevalence and predictors of HBsAg+ among all newly screened Chinese, n=2,088
N (%) Prevalence (95% CI) ORa (95% CI) p-value
Gender
 Male 1180 (43.5) 29.7 (27.1, 32.3) 2.3 (1.8, 3.0) <0.001
 Female 908 (56.5) 14.9 (12.6, 17.2) 1.0
Age
 18-29 511 (24.5) 34.2 (30.1, 38.3) 4.7 (1.6, 14.0) 0.005
 30-39 516 (24.7) 31.4 (27.4, 35.4) 4.5 (1.6, 13.1) 0.005
 40-49 494 (23.7) 18.2 (14.8, 21.6) 3.1 (1.1, 8.8) 0.039
 50-59 366 (17.5) 11.2 (8.0, 14.4) 1.9 (0.6, 5.6) 0.244
 60-69 113 (5.4) 7.1 (2.4, 11.8) 1.2 (0.3, 4.5) 0.735
 70+ 88 (4.2) 10.2 (3.9, 16.5) 1.0
Chinese Province
 Fujian 1117 (54.9) 33.1 (30.3, 35.9) 2.0 (1.5, 2.8) <0.001
 Other province 916 (45.1) 11.7 (9.6, 13.8) 1.0
Years in US
 Less than 5 438 (21.0) 26.9 (22.8, 31.1) 1.1 (0.8, 1.6) 0.540
 5 to 10 790 (37.8) 24.4 (21.4, 27.4) 0.9 (0.7, 1.2) 0.655
 More than 10 724 (34.7) 20.6 (17.7, 23.6) 1.0
 Unknown 136 (6.5) 18.4 (11.9, 24.9) 0.7 (0.4, 1.2) 0.235
Education
 Elementary school 327 (16.0) 24.2 (19.6, 28.8) 1.9 (1.1, 3.2) 0.017
 Junior high school 751 (36.8) 27.7 (24.5, 30.9) 1.6 (1.0, 2.6) 0.038
 High school/vocational school 702 (34.5) 22.8 (19.7, 25.9) 1.7 (1.1, 2.7) 0.024
 College 259 (12.7) 12.2 (8.2, 16.2) 1.0
Family History of HBV
 No 1151 (55.4) 18.7 (16.5, 21.0) 1.0
 Yes 396 (19.0) 32.1 (27.5, 36.7) 1.8 (1.4, 2.4) <0.001
 Not sure 532 (25.6) 26.3 (22.6, 30.0) 1.2 (1.0, 1.6) 0.102
a
Adjusted for all other variables in the model
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Table 3
Prevalence and predictors of HBsAg+ among all newly screened Koreans, n=1,551
N (%) Prevalence (95% CI) ORa (95% CI) p-value
Gender
 Male 690 (44.5) 4.9 (3.3, 6.5) 2.0 (1.1, 3.5) 0.018
 Female 861 (55.5) 2.9 (1.8, 4.0) 1.0
Age
 18-29 192 (12.4) 4.2 (1.4, 7.0) 1.1 (0.3, 4.3) 0.839
 30-39 207 (13.3) 3.9 (1.3, 6.5) 0.9 (0.2, 3.3) 0.831
 40-49 315 (20.3) 4.8 (2.4, 7.2) 1.4 (0.4, 4.4) 0.615
 50-59 412 (26.6) 4.9 (2.8, 7.0) 1.0 (0.3, 3.1) 0.939
 60-69 320 (20.6) 1.2 (0.0, 2.4) 0.3 (0.1, 1.1) 0.066
 70+ 105 (6.8) 3.8 (0.1, 7.5) 1.0
Korean Province
 Gyeonggi (Seoul) 725 (49.8) 3.3 (2.0, 4.6) 0.7 (0.4, 1.2) 0.208
 Not Gyeonggi 730 (50.2) 4.2 (2.7, 5.7) 1.0
Years in US
 Less than 5 175 (11.3) 4.6 (1.5, 7.7) 1.2 (0.5, 2.7) 0.740
 5 to 10 327 (21.1) 3.4 (1.4, 5.4) 0.7 (0.4, 1.6) 0.451
 More than 10 898 (57.9) 3.7 (2.5, 4.9) 1.0
 Unknown 151 (9.7) 4.6 (1.3, 7.9) 1.4 (0.6, 3.6) 0.438
Education
 Elementary school 90 (6.0) 3.3 (-0.4, 7.0) 1.1 (0.3, 4.2) 0.855
 Junior high school 109 (7.3) 1.8 (-0.7, 4.3) 0.6 (0.1, 2.8) 0.539
 High school/vocational school 547 (36.7) 4.0 (2.4, 5.6) 1.2 (0.6, 2.1) 0.635
 College 747 (50.0) 4.3 (2.9, 5.8) 1.0
Family History of HBV
 No 1039 (67.4) 3.2 (2.1, 4.3) 1.0
 Yes 113 (7.3) 11.5 (5.6, 17.4) 4.7 (2.3, 9.8) <0.001
 Not sure 390 (25.3) 3.1 (1.4, 4.8) 1.0 (0.5, 2.0) 0.963
a
Adjusted for all other variables in the model
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